$1.10
-0.13-10.57%
Last update: Nov 11, 4:59 PM
Bionano Genomics Inc
BNGONASDAQ
Bionano Genomics fell 32.1% from $1.62 to $1.10, behind the S&P 500's +9.8%. Its worst day was Mar 24 (−19.2%), and its low came Jul 30 at $1.06.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.59 beat the $-2.13 estimate on $7.4M revenue (est. $6.9M); Q4 revenue guidance of $7.5M–$7.9M against the $7.8M consensus.
+3.4% · S&P 500 0.0%
Bionano Genomics closed at its highest level of the year, 14.2% above where the year started.
Story events cover the past 12 months · Times ET
+2.2% · S&P 500 +0.5%
Bionano Genomics shares fell 11.6%, while the S&P 500 fell 0.3%.
−11.6% · S&P 500 −0.3%
EPS of $-0.77 beat the $-2.81 estimate on $8.0M revenue (est. $7.9M); FY revenue guidance of $30.0M–$33.0M against the $34.6M consensus.
−19.2%, the year's worst day · S&P 500 −0.3%
EPS of $-0.76 beat the $-0.92 estimate on $6.7M revenue (est. $6.6M); Q2 revenue guidance of $7.5M–$7.8M against the $7.5M consensus.
−4.8% · S&P 500 +0.8%
Bionano Genomics closed at its lowest level of the year, 34.6% below where the year started.
−2.8% · S&P 500 +1.7%
EPS of $-0.64 beat the $-0.68 estimate on $8.2M revenue (est. $7.5M); FY revenue guidance of $31.0M–$33.0M against the $32.1M consensus.
+2.6% · S&P 500 −0.3%
Bionano Genomics is surging Tuesday as investors weigh its growth strategy and favorable milestones for its genome mapping technology.
+17.3%, on 40M shares, the year's heaviest volume · S&P 500 −0.5%
EPS of $-0.54 missed the $-0.47 estimate on $8.3M revenue (est. $8.4M); FY revenue guidance of $31.0M–$33.0M against the $32.3M consensus.
−10.6%
Where it ended: a close of $1.10 on Nov 11, 2026.
Nothing in the past 12 months.
All BNGO dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BNGO and SPY from Benzinga historical bars. Not investment advice.
